JP2016507493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507493A5 JP2016507493A5 JP2015548291A JP2015548291A JP2016507493A5 JP 2016507493 A5 JP2016507493 A5 JP 2016507493A5 JP 2015548291 A JP2015548291 A JP 2015548291A JP 2015548291 A JP2015548291 A JP 2015548291A JP 2016507493 A5 JP2016507493 A5 JP 2016507493A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- neuropathic pain
- egfr
- group
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004296 neuralgia Diseases 0.000 claims description 57
- 208000021722 neuropathic pain Diseases 0.000 claims description 55
- 208000002193 Pain Diseases 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 18
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 18
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 14
- 229960001972 panitumumab Drugs 0.000 claims description 14
- 229960005395 cetuximab Drugs 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 231100000331 toxic Toxicity 0.000 claims description 10
- 230000002588 toxic effect Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 9
- 229960002584 gefitinib Drugs 0.000 claims description 9
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 8
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 8
- 229960001433 erlotinib Drugs 0.000 claims description 8
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 230000000202 analgesic effect Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 230000002503 metabolic effect Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 230000000472 traumatic effect Effects 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- -1 EGFR small molecule Chemical class 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 229960001686 afatinib Drugs 0.000 claims description 4
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
- 229930003827 cannabinoid Natural products 0.000 claims description 4
- 239000003557 cannabinoid Substances 0.000 claims description 4
- 229940111134 coxibs Drugs 0.000 claims description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229960003667 flupirtine Drugs 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 229960002870 gabapentin Drugs 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- 230000007774 longterm Effects 0.000 claims description 4
- 229950008001 matuzumab Drugs 0.000 claims description 4
- 229950008835 neratinib Drugs 0.000 claims description 4
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 229950010203 nimotuzumab Drugs 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 229960005489 paracetamol Drugs 0.000 claims description 4
- 229960001233 pregabalin Drugs 0.000 claims description 4
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 208000003130 Alcoholic Neuropathy Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000002720 Malnutrition Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010036105 Polyneuropathy Diseases 0.000 claims description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 208000020701 alcoholic polyneuropathy Diseases 0.000 claims description 2
- 229910052785 arsenic Inorganic materials 0.000 claims description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 2
- 239000010425 asbestos Substances 0.000 claims description 2
- 230000003376 axonal effect Effects 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 206010010121 compartment syndrome Diseases 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 229960003350 isoniazid Drugs 0.000 claims description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000003666 myelinated nerve fiber Anatomy 0.000 claims description 2
- 210000004126 nerve fiber Anatomy 0.000 claims description 2
- 231100000862 numbness Toxicity 0.000 claims description 2
- 235000018343 nutrient deficiency Nutrition 0.000 claims description 2
- 229940124636 opioid drug Drugs 0.000 claims description 2
- 230000007824 polyneuropathy Effects 0.000 claims description 2
- 229910052895 riebeckite Inorganic materials 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229910052716 thallium Inorganic materials 0.000 claims description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- 230000003156 vasculitic effect Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims 7
- 229940126586 small molecule drug Drugs 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 238000002638 palliative care Methods 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 230000002354 daily effect Effects 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 claims 1
- 229950008250 zalutumumab Drugs 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 description 5
- 230000008827 biological function Effects 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940065144 cannabinoids Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740876P | 2012-12-21 | 2012-12-21 | |
| US61/740,876 | 2012-12-21 | ||
| PCT/EP2013/003931 WO2014095088A1 (en) | 2012-12-21 | 2013-12-20 | Egfr targeted therapy of neurological disorders and pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018197322A Division JP2019023227A (ja) | 2012-12-21 | 2018-10-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016507493A JP2016507493A (ja) | 2016-03-10 |
| JP2016507493A5 true JP2016507493A5 (OSRAM) | 2017-02-09 |
Family
ID=50002662
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548291A Pending JP2016507493A (ja) | 2012-12-21 | 2013-12-20 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2018197322A Pending JP2019023227A (ja) | 2012-12-21 | 2018-10-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2022006083A Pending JP2022058654A (ja) | 2012-12-21 | 2022-01-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2024026738A Pending JP2024069254A (ja) | 2012-12-21 | 2024-02-26 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018197322A Pending JP2019023227A (ja) | 2012-12-21 | 2018-10-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2022006083A Pending JP2022058654A (ja) | 2012-12-21 | 2022-01-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2024026738A Pending JP2024069254A (ja) | 2012-12-21 | 2024-02-26 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20150320861A1 (OSRAM) |
| EP (1) | EP2935333A1 (OSRAM) |
| JP (4) | JP2016507493A (OSRAM) |
| KR (1) | KR102228358B1 (OSRAM) |
| CN (1) | CN104968680A (OSRAM) |
| AU (1) | AU2013362134B2 (OSRAM) |
| BR (1) | BR112015013849A2 (OSRAM) |
| CA (1) | CA2891855A1 (OSRAM) |
| EA (1) | EA037709B1 (OSRAM) |
| IL (1) | IL239542B (OSRAM) |
| MX (1) | MX376166B (OSRAM) |
| WO (1) | WO2014095088A1 (OSRAM) |
| ZA (1) | ZA201503579B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6851639B2 (ja) | 2015-07-16 | 2021-03-31 | ゾミクス バイオファーマ， インコーポレイテッド | プラチナ薬剤の毒性の予防方法 |
| CN110225754A (zh) * | 2016-11-22 | 2019-09-10 | 奥维德医疗公司 | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 |
| CU24555B1 (es) * | 2018-05-07 | 2021-12-08 | Centro De Investig Y Desarrollo De Medicamentos Cidem | Combinación a dosis fija de paracetamol:amitriptilina |
| WO2020115108A1 (en) | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2021191094A1 (en) | 2020-03-24 | 2021-09-30 | University Court Of The University Of Edinburgh | Erbb-targeted therapies for neuropathic pain |
| TWI807338B (zh) * | 2020-06-26 | 2023-07-01 | 美商美國禮來大藥廠 | 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途 |
| KR102536315B1 (ko) * | 2020-09-11 | 2023-05-25 | 아주대학교산학협력단 | 네라티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물 |
| TWI859538B (zh) * | 2021-05-21 | 2024-10-21 | 美商美國禮來大藥廠 | 靶向表皮調節素(epiregulin)之化合物及方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0531472T3 (da) | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| WO1993000917A1 (en) * | 1991-07-05 | 1993-01-21 | Seragen, Inc. | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5461146A (en) | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| DE69409641T2 (de) | 1993-05-28 | 1998-11-26 | Cephalon, Inc., West Chester, Pa. | Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5475110A (en) | 1994-10-14 | 1995-12-12 | Cephalon, Inc. | Fused Pyrrolocarbazoles |
| US5594009A (en) | 1994-10-14 | 1997-01-14 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5705511A (en) | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| CA2203809C (en) | 1994-10-28 | 2008-06-03 | James M. Wilson | Recombinant adenovirus and methods of use thereof |
| US5872154A (en) | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| US5650407A (en) | 1995-04-05 | 1997-07-22 | Cephalon, Inc. | Selected soluble esters of hydroxyl-containing indolocarbazoles |
| US6019978A (en) | 1995-06-05 | 2000-02-01 | The Wistar Institute Of Anatomy And Biology | Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| US5830730A (en) | 1997-05-08 | 1998-11-03 | The Regents Of The University Of California | Enhanced adenovirus-assisted transfection composition and method |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| JP2003528029A (ja) | 1998-08-14 | 2003-09-24 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 遺伝子治療用のアデノウイルス配合物 |
| WO2000012738A1 (en) | 1998-08-27 | 2000-03-09 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
| US7060436B2 (en) | 2000-06-17 | 2006-06-13 | Third Wave Technologies, Inc. | Nucleic acid accessible hybridization sites |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| ES2566561T3 (es) | 2001-07-12 | 2016-04-13 | University Of Massachusetts | Producción in vivo de ARN pequeños de interferencia que median el silenciamiento génico |
| EP1474433A4 (en) | 2002-02-20 | 2005-02-23 | Sirna Therapeutics Inc | VALIDATION AND IDENTIFICATION OF RNA INTERFERENCE FACILITATED TARGETS USING SHORT INTERFERENT NUCLEIC ACID (siNA) |
| US20080226553A1 (en) | 2002-09-27 | 2008-09-18 | Cold Spring Harbor Laboratory | Cell-Based Rna Interference and Related Methods and Compositions |
| US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
| GB0320793D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Chemical process |
| WO2005038054A1 (en) | 2003-10-20 | 2005-04-28 | Zicai Liang | METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES |
| GB0327726D0 (en) | 2003-11-28 | 2003-12-31 | Isis Innovation | Method |
| JP4969440B2 (ja) | 2004-04-08 | 2012-07-04 | デビッド， ビー． エイガス， | 疼痛治療のためのＥｒｂＢアンタゴニスト |
| JP5601756B2 (ja) | 2004-12-17 | 2014-10-08 | ベス イスラエル デアコネス メディカル センター， インコーポレイテッド | 細菌によって媒介される遺伝子サイレンシングのための組成物およびその使用方法 |
| EP2089521A1 (en) | 2006-02-08 | 2009-08-19 | Ercole Biotech, Inc. | Soluble tnf receptors and their use in treatment of disease |
| US7741273B2 (en) * | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| US20100062994A1 (en) | 2006-07-14 | 2010-03-11 | Santaris Pharma A/S | Adenosine Receptor Antagonists |
| CU23526B6 (es) * | 2006-10-03 | 2010-05-19 | Ct Ingenieria Genetica Biotech | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
| MX2009003729A (es) | 2006-10-09 | 2009-04-22 | Santaris Pharma As | Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a. |
| WO2009048947A1 (en) * | 2007-10-09 | 2009-04-16 | Board Of Regents, The University Of Texas System | Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors |
| CA2741089A1 (en) * | 2008-10-22 | 2010-04-29 | Genentech, Inc. | Modulation of axon degeneration |
| JP5918693B2 (ja) * | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| LT2729173T (lt) * | 2011-07-06 | 2016-10-10 | Sykehuset Sorlandet Hf | Egfr taikinių terapija |
-
2013
- 2013-12-20 CA CA2891855A patent/CA2891855A1/en not_active Abandoned
- 2013-12-20 WO PCT/EP2013/003931 patent/WO2014095088A1/en not_active Ceased
- 2013-12-20 JP JP2015548291A patent/JP2016507493A/ja active Pending
- 2013-12-20 BR BR112015013849A patent/BR112015013849A2/pt not_active Application Discontinuation
- 2013-12-20 KR KR1020157019856A patent/KR102228358B1/ko active Active
- 2013-12-20 CN CN201380067506.8A patent/CN104968680A/zh active Pending
- 2013-12-20 US US14/654,180 patent/US20150320861A1/en not_active Abandoned
- 2013-12-20 EA EA201500670A patent/EA037709B1/ru unknown
- 2013-12-20 MX MX2015007719A patent/MX376166B/es active IP Right Grant
- 2013-12-20 EP EP13824308.4A patent/EP2935333A1/en not_active Withdrawn
- 2013-12-20 AU AU2013362134A patent/AU2013362134B2/en not_active Ceased
-
2015
- 2015-05-21 ZA ZA2015/03579A patent/ZA201503579B/en unknown
- 2015-06-18 IL IL239542A patent/IL239542B/en active IP Right Grant
-
2016
- 2016-09-20 US US15/270,525 patent/US10611844B2/en active Active
-
2018
- 2018-10-19 JP JP2018197322A patent/JP2019023227A/ja active Pending
-
2020
- 2020-03-19 US US16/824,108 patent/US11396548B2/en active Active
-
2022
- 2022-01-19 JP JP2022006083A patent/JP2022058654A/ja active Pending
- 2022-07-15 US US17/865,481 patent/US20230016235A1/en active Pending
-
2024
- 2024-02-26 JP JP2024026738A patent/JP2024069254A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pribish et al. | A review of nonanesthetic uses of ketamine | |
| Kim et al. | Low-dose naltrexone for chronic pain: update and systemic review | |
| JP2016507493A5 (OSRAM) | ||
| Mercadante et al. | Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study | |
| Movafegh et al. | Naloxone infusion and post‐hysterectomy morphine consumption: a double‐blind, placebo‐controlled study | |
| Braverman et al. | Using gabapentin to treat failed back surgery syndrome caused by epidural fibrosis: A report of 2 cases | |
| Silva Filho et al. | Analgesic effect of magnesium sulfate during total intravenous anesthesia: randomized clinical study | |
| Khafagy et al. | Efficacy of epidural dexamethasone versus fentanyl on postoperative analgesia | |
| JP2015187125A5 (OSRAM) | ||
| Chen et al. | Preoperative and postoperative analgesic techniques in the treatment of patients undergoing transabdominal hysterectomy: a preliminary randomized trial | |
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| Rimaz et al. | Effect of gabapentin on morphine consumption and pain after surgical debridement of burn wounds: a double-blind randomized clinical trial study | |
| Davidson et al. | Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index≥ 27 kg/m2 | |
| Conn | The story behind the use of glucocorticoids in the treatment of rheumatoid arthritis | |
| Moseley et al. | Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three phase III studies | |
| Wojcikowski et al. | New Concepts of Chronic Pain and the Potential Role of Complementary Therapies. | |
| EP2341900B1 (en) | A medicinal product and treatment | |
| Tramèr et al. | Magnesium Bier's block for treatment of chronic limb pain: a randomised, double-blind, cross-over study | |
| Lamond et al. | Addition of droperidol to morphine administered by the patient-controlled analgesia method: what is the optimal dose? | |
| Marinangeli et al. | Improved cancer pain treatment using combined fentanyl‐TTS and tramadol | |
| Rakhman et al. | Repeated and escalating preoperative subanesthetic doses of ketamine for postoperative pain control in patients undergoing tumor resection: a randomized, placebo-controlled, double-blind trial | |
| CN105209044B (zh) | 用于疼痛病症的治疗性米氮平组合物 | |
| KR20240069750A (ko) | 신경 장애의 치료 | |
| Gombotz et al. | Opiate sparing effect of fixed combination of diclophenac and orphenadrine after unilateral total hip arthroplasty: A double-blind, randomized, placebo-controlled, multi-centre clinical trial | |
| US11752143B2 (en) | Methods of using low dose naltrexone to treat chronic pain |